Pradaxa.ie

For Republic of Ireland healthcare
professionals only

FOR PREVENTION OF STROKE OR SYSTEMIC EMBOLISM IN ADULT PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION,
PLUS ONE OR MORE RISK FACTORS^1,2

Educational Pack

Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥75 years; heart failure (NYHA Class ≥II); diabetes mellitus; hypertension.^1,2

Report adverse events

Adverse events should be reported. Reporting forms and information can be found at www.hpra.ie/homepage/about-us/report-an-issue.

Adverse events should also be reported to Boehringer Ingelheim Drug Safety on 1850 946100.

Adverse Events

Adverse events should be reported. Reporting forms and information can be found at www.hpra.ie/homepage/about-us/report-an-issue.

Adverse events should also be reported to Boehringer Ingelheim Drug Safety on 1850 946100.

References:

Boehringer Ingelheim. Pradaxa^® 150mg hard capsules Summary of Product Characteristics.
Boehringer Ingelheim. Pradaxa^® 110mg hard capsules Summary of Product Characteristics.